Oct. 29, 2024 -- Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced the closing of an oversubscribed $62M Series C funding round. The Series C financing round was led by New Enterprise Associates (NEA) with participation from Revolution Growth and other existing insiders. This new capital infusion will enable Pathos to expand its team of world-class scientists and engineers, accelerate the development of

Oct. 22, 2024 (GLOBE NEWSWIRE) -- RespiriNTM Programme allows BioVersys’ NTM project to access up to €2 million of non-dilutive funding BioVersys taps into key expertise of the established RespiriNTM consortium members and will lead development of its candidates through preclinical and clinical studies BioVersys’ NTM candidates are derived from the company’s proprietary Ansamycin Chemistry platform and are being developed to address difficult-to-treat Mycobacterium avium complex (MAC) and Myco

-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 -- Oct. 21, 2024 -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Cardiopulmonary and Neurodegenerative disease through Abelson Tyrosine Kinase inhibition, tod

€451M Revolving Credit Facility refinanced with a maturity extended to February 2029 Issuance of a €200M Perpetual Deeply Subordinated Hybrid Bond subscribed by Sanofi €54M product capacity reservation for five products and further amendments to the global Manufacturing and Supply Agreement (MSA) agreed with Sanofi “The completion of the financing is an instrumental step in the execution of EUROAPI’s strategic roadmap” said Ludwig de Mot, Chief Executive Officer. “Combined with further developm

Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executed Development work is based on ModeX proprietary MSTAR technology that incorporates multiple antibody binding sites into a single molecule Oct. 07, 2024 -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces it has been awarded $35 million of additional funding under an existing contract

Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic One of the largest private Italian Biotech company financings to date Financing co-led by Sofinnova Partners, XGEN Venture and CDP Venture Capital forming a strong syndicate with Indaco SGR Funds dedicated to advancing off-the-shelf pediatric gene therapy for Methylmalonic Acidemia (MMA) into the clinic, and to bolstering the Company’s gene therapy pipeline 25 Sep

Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testing SZN-413 is a bi-specific antibody targeting Frizzled Class Receptor 4 (Fzd4) mediated Wingless/Integrated (Wnt) signaling, designed using Surrozen’s SWAP™ technology SZN-413 offers the possibility of restoring retinal function in patients living with retinal vascular diseases Sept. 24, 2024 -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN) announced that Boehringer Ingelheim will

Sept. 19, 2024 -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the National Institutes of Health (NIH), National Institute on Aging have awarded a $4 Million grant to Dr. Howard Weiner as principal investigator at Brigham and Women’s Hospital to be the key research site, to s

Sept. 12, 2024 -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract modification executing an option period by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), valued at $41.9 million, for drug substance engineering and scale-up process validation, long term stability, and commercial readiness in support o

Sept. 05, 2024 -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a non-dilutive grant from Target ALS Foundation. It is one of five recipients of the 2024 In Vivo Target Validation grants in collaboration with Biospective. The funding will be used to support its discovery programme for a treatment for Amyotrophic Lateral Sclerosis (ALS) (also known as Lou Gehrig’s disease or Motor Nuerone Disease)